date,title,source
Nov-01-18,Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting,GlobeNewswire
Nov-09-18,Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting,GlobeNewswire
Nov-15-18,Celyad to Participate at Upcoming Healthcare Conferences,GlobeNewswire
Nov-21-18,Celyad Announces Third Quarter 2018 Business Update,GlobeNewswire
Nov-30-18,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",Benzinga
Nov-30-18,"Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101",GlobeNewswire
Dec-04-18,Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting,GlobeNewswire
Jan-07-19,Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS,GlobeNewswire
Feb-21-19,Celyad Announces February and March 2019 Investor Conference Schedule,GlobeNewswire
